ClinicalTrials.gg
CompletedNCT00109668Updated Dec 8, 2021

Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids

A Phase 3 interventional study of beclomethasone dipropionate (QVAR) in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 32 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-12-08.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2004, registered May 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
415
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
9th of 40
415 · median 67
Started
2004
with 5 others
Phase 3
20 of 40
none open now
Registered
3rd of 40
by date
Lead sponsor
7 of 40
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 40 studies testing beclomethasone in Asthma, this one is the 9th largest by enrollment, is one of 6 that started in 2004, is one of 20 in phase 3, and was the 3rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

QVAR in a standard press and breath inhaler (QVAR-MDI) has been approved by the Food and Drug Administration (FDA) for use in the United States. The purpose of this study is to determine the level of asthma control when comparing the safety and effectiveness of QVAR in two different devices, a metered dose inhaler (MDI) and a breath operated inhaler (BOI).

Read the detailed description

This investigation is a multicenter, randomized, placebo and active controlled, double-blind, double-dummy, parallel-group study to evaluate the safety and efficacy of two doses of QVAR-BOI in adolescents and adults.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-nursing female at least 12 years of age at the screening visit. NOTE: Females of may be included if they are practicing an acceptable method of for at least 2 months and have a negative urine pregnancy test at the screening visit.
  • Asthma ( 60-85% predicted)
  • Ability to perform acceptable and reproducible spirometry
  • Ability to perform PEF determinations
  • Reversible bronchoconstriction as verified by a greater than or equal to 12% increase in FEV1 following inhalation of albuterol. Historical reversibility will be allowed
  • Patients must be on a stable regimen of daily-inhaled at low to medium doses for at least 30 days prior to screening.
  • Otherwise healthy individuals with clinically-acceptable medical history, physical examination, vital signs, 12 lead , and clinical laboratory parameters within the acceptable ranges for asthma patients.
  • Non-smoker for at least one year prior to the screening visit and maximum smoking history of ten-pack years
  • The patient must be willing to give written and be able to adhere to the dose and visit schedules. If applicable, parent or guardian must also provide consent.

Exclusion criteria

Exclusion Criteria:

  • Allergy or sensitivity to BDP (beclomethasone dipropionate) or to other components of the formulations used in the CTM
  • Patients demonstrating an increase or decrease in >20% between the screening and baseline visit.
  • Patients requiring the use of >12 puffs per day of albuterol for any 3 consecutive days between the screening and baseline visits.
  • Patients who are unable to use an MDI without a spacer device. (Use of spacers is prohibited during the course of the study.)
  • Patients who have been treated with methotrexate, cyclosporin, gold or other cytotoxic agents for the control of asthma or for a concurrent condition within the last 3 months.
  • Patients who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy for rhinitis.
  • Patients with evidence of oropharyngeal candidiasis.
  • Exposure to drugs within 30 days prior to the screening visit
  • Require continuous treatment with beta blockers (administered by any route), MAO inhibitors, leukotriene modifiers, tricyclic antidepressants, anticholinergics, inhaled nedocromil or cromolyn, or nebulized therapy (excluding sponsor provided albuterol MDI) following the screening visit.
  • Patients who have received any of the following treatments or met any of the following conditions within six weeks prior to the screening visit: *oral or injectable ; *an upper respiratory tract infection and/or sinusitis associated with exacerbation of asthmatic symptoms; *emergency room treatment or hospitalization for asthmatic symptoms
  • Inability to tolerate or unwillingness to comply with required for all applicable medications
  • Treatment at any time for life-threatening asthmatic episodes
  • History or presence of any non-asthmatic acute or chronic lung disease
  • History of glaucoma, ocular hypertension or cataracts
  • Presence of systemic fungal, bacterial, viral or parasitic infections and/or ocular herpes simplex
  • Known or suspected substance abuse (e.g., alcohol, marijuana, etc.)
  • Patients who are known to be positive
  • Unlikely to be compliant, take study medication as directed, complete the diary cards, or attend scheduled clinic visits as required.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
415 participants
06

Study locations

32 sites
  • Alabama Allergy and Asthma
    Birmingham, Alabama 35209, United States
  • Allergy and Asthma Specialists
    Huntington Beach, California 92647, United States
  • West Coast Clinical Trials
    Long Beach, California 90806, United States
  • Allergy Research Foundation
    Los Angeles, California 90025, United States
  • UCLA David Geffen School of Medcine
    Los Angeles, California 90095, United States
  • Clinical Trials of Orange County, Inc.
    Orange, California 92868, United States
  • Allergy Associates Medical Group
    San Diego, California 92120, United States
  • Allergy and Asthma Medical Group
    Walnut Creek, California 94598, United States
  • Boulder Medical Center
    Boulder, Colorado 80304, United States
  • Asthma and Allergy Associates, PC
    Colorado Springs, Colorado 80907, United States
  • Colorado Allergy and Asthma Center
    Denver, Colorado 80230, United States
  • Asthma and Allergy Research Center
    Sarasota, Florida 34233, United States
  • Allergy and Asthma DTC
    Tallahassee, Florida 32308, United States
  • Aero Allergy Research Labs of Savannah, Inc
    Savannah, Georgia 31406, United States
  • Pulmonary Consultants of North Idaho
    Coeur d'Alene, Idaho 83814, United States
  • Sneeze, Wheeze and Itch Associates
    Normal, Illinois 61761, United States
  • Family Allergy and Asthma Research Center
    Louisville, Kentucky 40215, United States
  • Bendel Medical Research
    Lafayette, Louisiana 70503, United States
  • Northeast Medical Research Associates
    North Dartmouth, Massachusetts 02747, United States
  • The Clinical Research Center
    Saint Louis, Missouri 63141, United States
  • Dr. Alan Kaufman
    Bronx, New York 10465, United States
  • Regional Allergy and Asthma Consultants
    Asheville, North Carolina 28805, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Allergy, Asthma & Dermatology Research Center
    Lake Oswego, Oregon 97035, United States
  • Allergy Associates Research Center
    Portland, Oregon 97213, United States
  • National Allergy and Asthma and Urticaria Centers of Charleston, PA
    Charleston, South Carolina 29407, United States
  • Allergy and Asthma Associates
    Houston, Texas 77054, United States
  • Dr. Emory Robinette
    Abingdon, Virginia 24210, United States
  • Belligham Asthma and Allergy
    Bellingham, Washington 98225, United States
  • Pulmonary Consultants
    Tacoma, Washington 98405, United States
  • Morgantown Pulmonary Associates
    Morgantown, West Virginia 26505, United States
  • Ponce School of Medicine
    Ponce, 00732, Puerto Rico
07

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2004 to primary completion in Sep 2006, 25 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 25 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2005
First posted
May 3, 2005
StartActual
Jul 31, 2004
Primary completionActual
Sep 30, 2006
CompletionActual
Sep 30, 2006
Last update
Dec 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00109668
Responsible party
Sponsor
First posted
May 3, 2005
Start date
Jul 31, 2004
Primary completion
Sep 30, 2006
Completion
Sep 30, 2006
Last update
Dec 8, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion